Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Integrin Inhibitor
Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that acts as an integrin inhibitor by binding to integrin receptors αvβ3 and αvβ5. This binding disrupts cell adhesion processes, making it valuable in research applications related to cell migration, angiogenesis, and tumor progression. With estimated IC50 values of approximately 5 μM and 6.5 μM for its primary targets, GRGDS is a crucial tool for studies involving extracellular matrix interactions and integrin-mediated signaling pathways. -
αvβ3/αvβ5 integrin/IGF1R Inhibitor
Synstatin (92-119) is a potent inhibitor targeting αvβ3/αvβ5 integrins and IGF1R, exhibiting anti-angiogenic, anti-proliferative, antioxidant, and anti-tumor properties. It functions by competitively inhibiting the interaction of syndecan-1 with these integrins and IGF1R, thereby disrupting the ternary complex formation and blocking critical downstream signaling pathways. This compound is particularly relevant for research in cancer biology, especially in studies focused on angiogenesis and hepatocellular carcinoma. -
ανβ1 Integrin Inhibitor
PLN-1474 is a selective ανβ1 integrin inhibitor with an IC50 value of less than 50 nM. This compound demonstrates significant biological activity by reducing pSMAD3/SMAD3 levels, hepatic collagen gene expression, and hepatic OHP concentration in mouse models of liver fibrosis. PLN-1474 is valuable for research focused on the prevention and treatment of fibrotic and cirrhotic diseases. -
Integrin Signaling Inhibitor
Integrin signaling inhibitor, mP13, targets integrin signaling pathways, effectively inhibiting both inside-out and outside-in signaling mechanisms. This compound disrupts critical processes such as fibrinogen binding, platelet adhesion, and clot retraction. Due to its significant biological activity, mP13 is an essential reagent for studies in hemostasis, thrombosis, and cardiovascular research applications. -
Integrin αvβ3 Inhibitor
LXW7 is an integrin αvβ3 inhibitor that features a cyclic peptide structure incorporating Arg-Gly-Asp (RGD). It demonstrates a high binding affinity to the αvβ3 integrin with an IC50 value of 0.68 μM. LXW7 is known to enhance the phosphorylation of VEGFR-2 and activate ERK1/2, contributing to its anti-inflammatory properties. This compound can be utilized in research focusing on angiogenesis, cancer progression, and inflammatory processes. -
Integrin Inhibitor
Rondaptivon pegol is a pegylated aptamer that acts as an integrin inhibitor by specifically blocking the interaction between von Willebrand factor (VWF) and platelet glycoprotein GPIb. This inhibition plays a critical role in preventing arterial thrombosis, making Rondaptivon pegol a valuable tool in cardiovascular research and the study of thrombotic disorders. Its unique mechanism of action positions it as a potential therapeutic candidate for conditions associated with excessive platelet aggregation. -
α4β7 Integrin Inhibitor
Emvistegrast is a quinolone derivative that functions as a selective inhibitor of the α4β7 integrin. This compound demonstrates significant potential in modulating immune responses and is particularly relevant for research into inflammatory bowel disease and other conditions associated with α4β7 integrin activity. Its oral bioavailability allows for convenient administration in various preclinical studies, facilitating investigations into its therapeutic efficacy. -
Integrin Inhibitor
Integrin-IN-2 is a pan αv integrin inhibitor that demonstrates oral bioavailability. It effectively enhances the binding affinities for αvβ6, αvβ3, αvβ5, and αvβ8, with pIC50 values of 7.8, 8.4, 8.4, and 7.4, respectively. This compound is valuable for research applications focused on cancer metastasis and fibrosis, providing a tool for investigating integrin-mediated cellular processes. -
αVβ8 Integrin Inhibitor
αVβ8-IN-1 is an αVβ8 integrin inhibitor that targets integrin-mediated signaling pathways. This compound has demonstrated efficacy in inhibiting tumor growth in models such as EMT6, CT26, KPC, and TKCC-10. It serves as a valuable research tool for studies investigating idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP), and various tumor types. -
Integrin Inhibitor
FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro is a fluorescently labeled integrin inhibitor designed to inhibit the binding of tumor cells to endothelial cells lining blood vessels. This compound, based on the GRGDSP peptide sequence, effectively reduces tumor cell adherence and has potential applications in cancer research, particularly in studies focused on metastasis and angiogenesis. Its fluorescent properties facilitate visualization and tracking in cellular studies. -
αvβ6/αvβ1 Integrin Inhibitor
Bexotegrast hydrochloride is a selective dual inhibitor of the αvβ1 and αvβ6 integrins. By inhibiting these integrins, Bexotegrast hydrochloride effectively blocks the activation of TGF-β1, which is crucial in preventing the fibrotic growth in tissues associated with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). This compound serves as a valuable tool for research into fibrosis-related pathologies and therapeutic interventions for fibrotic diseases. -
α4β7 Integrin Inhibitor
α4β7 Integrin-IN-1 is a highly effective inhibitor of the α4β7 integrin, specifically blocking its interaction with MadCAM-1 with an EC50 value of 0.05 nM. This compound is primarily utilized in research applications related to inflammatory bowel disease, providing insights into therapeutic strategies targeting integrin-mediated pathways. Its high potency makes it a valuable tool for studying cell adhesion processes and related inflammatory mechanisms. -
α5β1 Integrin Inhibitor
α5β1 integrin-IN-1 is a highly selective inhibitor of the α5β1 integrin, demonstrating a pIC50 of 9.4 and over 10,000-fold selectivity for α5β1 compared to αVβ3 (pIC50 = 5.5). This compound effectively reduces airway smooth muscle tension by disrupting cellular tethering mechanisms. With favorable inhalation pharmacokinetics in rodent models, α5β1 integrin-IN-1 is a valuable tool for researchers investigating asthma and related respiratory conditions. -
Integrin Inhibitor
ATL 1102 is a second-generation antisense oligonucleotide targeting the CD49d mRNA, acting as an integrin inhibitor. This compound demonstrates significant biological activity in modulating immune responses and has potential applications in treating autoimmune disorders and other inflammatory conditions. Researchers can utilize ATL 1102 to investigate the role of integrin signaling in various disease models. -
Integrin β(3) Inhibitor
mP6 (Myr-FEEERA-OH) is an integrin β3 inhibitor that specifically targets the interaction between Gα13 and integrin β3, preserving talin-dependent integrin function. This myristoylated peptide effectively blocks GTP usage in Rac1, Rap1, and Rab7, thereby inhibiting the infection process in CHO-A24 cells. mP6 is valuable for research applications involving integrin signaling and modulation of cell adhesion pathways. -
α2β1 integrin Inhibitor
BTT-3034 is a sulfonamide derivative that selectively inhibits the α2β1 integrin, targeting its role in cell adhesion. It demonstrates significant biological activity by inhibiting cell adhesion to rat tail collagen I with an EC50 of 160 nM and a maximal effect of 86%. Additionally, BTT-3034 effectively inhibits collagen binding in an α2 integrin variant that carries the conformationally activating E318W mutation, making it a valuable tool for research in cellular adhesion and integrin biology. -
αLβ2 Integrin Inhibitor
αLβ2 integrin-IN-1 is an inhibitor of the αLβ2 integrin, designed to obstruct αLβ2 integrin-mediated cell adhesion. This compound is valuable for investigating the role of αLβ2 integrin in various inflammatory conditions and can aid in exploring therapeutic interventions for diseases characterized by aberrant cell adhesion and migration. Its application can enhance understanding of the molecular mechanisms underlying inflammatory responses. -
Integrin Inhibitor
αvβ1 integrin-IN-2 is a highly effective inhibitor of integrins αvβ1 and α5β1, exhibiting IC50 values of 0.9 nM and 33 nM, respectively. This compound also demonstrates inhibitory activity against additional integrins, including IC50s of 380 nM for αvβ3, 280 nM for αvβ5, 230 nM for αvβ6, and 87 nM for αvβ8, as determined by the SPRA assay. αvβ1 integrin-IN-2 is valuable for research applications focused on integrin-mediated signaling pathways and cell adhesion processes. -
Integrin Inhibitor
Gly-Arg-Gly-Asp-Ser TFA is a pentapeptide that serves as an integrin inhibitor. It effectively binds to the integrin receptors αvβ3 and αvβ5, exhibiting an estimated IC50 of approximately 5 μM and 6.5 μM, respectively. This compound is valuable in research applications focused on cell adhesion, migration, and signaling processes relevant to various pathologies, including cancer and tissue engineering. -
αvβ6 Integrin Inhibitor
GSK3335103 is an orally active, non-peptide inhibitor of the αvβ6 integrin, demonstrating a potent affinity with a pIC50 value of 8. This compound is primarily utilized in research focused on pulmonary fibrosis, aiding in the understanding of its pathophysiology and potential therapeutic interventions. The inhibition of αvβ6 integrin by GSK3335103 can provide insights into cellular mechanisms involved in fibrotic processes. -
Integrin α4β1 Inhibitor
TBC3486 is a selective inhibitor of integrin α4β1. This compound enhances the sensitivity of leukemia cells to chemotherapy, demonstrating its potential as a chemosensitizer. TBC3486 shows efficacy in preclinical models related to integrin α4-dependent inflammatory and autoimmune conditions, notably in a mouse model of autoimmune encephalomyelitis. It is a valuable reagent for research focused on precursor B-cell acute lymphoblastic leukemia. -
α4 integrin Inhibitor
6-B345TTQ is an α4 integrin inhibitor that disrupts the interaction between α4 integrin and Leupaxin. This compound exhibits significant potential in the study of inflammatory processes and related pathways. Its inhibitory activity on α4 integrin places it at the forefront of research involving immune modulation and inflammation-related conditions. -
Integrin Receptors Inhibitor
Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide functioning as an integrin receptor inhibitor. It effectively downregulates oxidative stress and restores homeostasis, targeting three integrin receptors associated with dry age-related macular degeneration (AMD). This compound is valuable for research applications focused on retinal health and the mechanisms underlying AMD. -
αvβ6 Integrin Inhibitor
αvβ6 integrin inhibitor 2 is a selective inhibitor of the αvβ6 integrin, demonstrating an IC50 of 96.5 nM. This compound effectively modulates integrin-mediated cell adhesion and signaling pathways, making it valuable for research in cancer metastasis, fibrosis, and tissue regeneration. Its ability to inhibit αvβ6 integrin activity positions it as a crucial tool for studying integrin-related biological processes. -
Integrin α5β1 Inhibitor
CLT-28643 is an integrin α5β1 inhibitor that plays a significant role in modulating cellular adhesion and migration. It effectively reduces the overexpression of integrin α5β1 in post-surgical blebs, thereby facilitating the wound healing process. This compound is valuable for research in tissue regeneration and healing mechanisms. -
Integrin Inhibitor
RUC-1 is a specific inhibitor of the αIIbβ3 integrin. This compound effectively inhibits fibrin deposition and platelet aggregation in mouse models expressing hybrid hαIIb/mβ3 receptors. RUC-1 demonstrates significant antithrombotic effects, making it a valuable tool for studying integrin-related processes and potential therapeutic applications in coagulation disorders. -
Microtubule/Tubulin Inhibitor
D011-2120 is a microtubule/tubulin inhibitor that disrupts microtubule polymerization, interfering with the Golgi complex's function. This inhibition hampers viral trafficking to the plasma membrane, thereby blocking virus egress. D011-2120 is valuable in virology research for studying antiviral mechanisms and cellular pathways involved in viral replication and dissemination. -
KIF18A Inhibitor
Sovilnesib is a selective inhibitor of the kinesin-like protein KIF18A, exhibiting an IC50 value of 0.071 μM. This potent, orally active compound is utilized in cancer research, where it aids in the investigation of microtubule dynamics and the mechanisms of tumor cell proliferation. Sovilnesib facilitates the study of KIF18A's role in cancer progression and provides insights into potential therapeutic strategies targeting this protein. -
HSET Inhibitor
CCT368772 is a selective kinesin HSET inhibitor, demonstrating an IC50 value of 0.019 μM in the HSET ADP-Glo assay. This compound shows high selectivity for HSET, with minimal activity against Eg5 (IC50 >200 μM). CCT368772 is suitable for research into hyperproliferative diseases, including various cancer types, providing a valuable tool for understanding and potentially targeting these pathologies. -
KIF18A Inhibitor
KIF18A-IN-6 is a potent inhibitor of KIF18A, exhibiting an IC50 of 0.016 μM against KIF18A's microtubule-dependent ATPase activity. This compound is valuable for investigating the role of KIF18A in cellular processes, including mitotic spindle assembly and chromosome alignment. Researchers can utilize KIF18A-IN-6 to explore therapeutic strategies targeting cancer cell division by modulating KIF18A activity. -
KIF18A Inhibitor
KIF18A-IN-1 is a potent inhibitor of the mitotic kinesin KIF18A, demonstrating significant anti-tumor activity. By targeting KIF18A, this compound has the potential to activate mitotic checkpoints, selectively inducing apoptosis in chromosomally unstable cancer cells. It is a valuable tool for research focused on cancer biology and the development of targeted cancer therapeutics. -
KIF18A Inhibitor
AM-5308 is a potent inhibitor of KIF18A, showcasing an IC50 value of 47 nM. By inhibiting KIF18A-mediated microtubule ATPase activity, AM-5308 effectively activates mitotic checkpoints and regulates critical cell division processes, including chromosome segregation and spindle assembly. This compound demonstrates notable antitumor activity, making it a valuable tool for cancer research and studies focused on mitotic regulation. -
KIF18A Inhibitor
AM-9022 is a potent and selective inhibitor of KIF18A, primarily targeting the kinesin family of motor proteins involved in cellular transport and mitosis. This compound demonstrates significant inhibitory activity, making it a valuable tool for research into cancer mechanisms and potential therapeutic strategies. Its efficacy in modulating KIF18A function provides insights into the role of mitotic regulation in tumorigenesis. -
Kinesin-5 Inhibitor
PVZB1194 is a selective inhibitor of Kinesin-5 ATPase, targeting the α4/α6 site within the motor domain in a nucleotide-competitive manner. With an IC50 of 0.12 μM for KSP ATPase, PVZB1194 effectively induces mitotic arrest characterized by the formation of monopolar spindles, leading to inhibition of HeLa cell proliferation (IC50: 5.5 μM). This compound is valuable for research applications focusing on tumor biology and cell division regulation. -
CENP-E Inhibitor
PF-2771 is a selective inhibitor of centromere protein E (CENP-E) that inhibits its motor activity with an IC50 of 16.1 nM. This compound exhibits significant potential as an anticancer agent by disrupting mitotic processes and leading to cell cycle arrest. PF-2771 is utilized in research investigating the mechanisms of cancer cell division and has applications in the development of novel cancer therapeutics. -
KIF18A Inhibitor
KIF18A-IN-13 is a potent inhibitor of KIF18A, demonstrating significant anticancer activity in vivo. This compound is particularly applicable in research focusing on ovarian cancer, providing a valuable tool for studying the mechanisms of tumor growth and potential therapeutic interventions. -
CENP-E Inhibitor
Syntelin is a selective inhibitor of centromere protein E (CENP-E) with an IC50 of 160 nM. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its ability to modulate CENP-E function underscores its potential applications in studying mitotic processes and exploring therapeutic strategies for cancer treatment. -
KIFC1 Inhibitor
SR31527 chloride is a potent inhibitor of KIFC1, exhibiting an IC50 value of 6.6 µM. This compound effectively reduces cell viability and impairs colony formation in cellular assays. Its biological activity makes it a valuable tool for investigating the roles of KIFC1 in cell proliferation and cancer research. -
KIF18A Inhibitor
KIF18A-IN-2 is a selective inhibitor of KIF18A with an IC50 of 28 nM. This compound effectively induces mitotic arrest, leading to an increased population of mitotic cells in tumor tissues. KIF18A-IN-2 is suitable for use in cancer research, providing valuable insights into the mechanisms of cell division and the potential for therapeutic interventions. -
KIF18A Inhibitor
KIF18A-IN-3 is a selective inhibitor of kinesin motor protein KIF18A, with an IC50 of 61 nM. This compound induces significant mitotic arrest and enhances the population of mitotic cells within tumor tissues. KIF18A-IN-3 is suited for cancer research applications, providing insights into the roles of mitotic regulation and potential therapeutic strategies targeting KIF18A. -
KIF18A Inhibitor
KIF18A-IN-9 is a potent inhibitor of kinesin family member 18A (KIF18A), exhibiting an IC50 value of 3.8 nM. This compound demonstrates significant anticancer activity, showing IC50 values below 100 nM in ovarian cancer OVCAR3 and breast cancer MDA-MB-157 cell lines. KIF18A-IN-9 serves as a valuable tool for investigating the role of KIF18A in mitotic processes and its potential therapeutic implications in cancer research. -
KSP Inhibitor
Filanesib TFA is a selective kinesin spindle protein (KSP) inhibitor, demonstrating an IC50 of 6 nM against human KSP. This compound effectively induces apoptosis in vitro, providing potent anti-proliferative activity. Filanesib TFA is utilized in research applications focused on cancer biology and exploring novel therapeutic strategies targeting mitotic processes. -
Eg5 Inhibitor
(S)-Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5, known for its ability to disrupt mitotic spindle formation. This compound exhibits significant antiproliferative activity against various cancer cell lines by inducing a monopolar spindle formation, effectively arresting mammalian cells in mitosis. (S)-Monastrol serves as a valuable tool for research into cancer biology and the mechanisms of cell division. -
Eg5 Inhibitor
SB-743921 free base is a highly selective inhibitor of the mitotic kinesin Eg5, exhibiting a Ki of 0.1 nM. This compound effectively induces mitotic arrest, inhibits cell cycle progression, and promotes apoptosis. It serves as a valuable tool in cancer research, particularly in the study of myeloma, leukemia, and other malignancies. -
HSET Motor Inhibitor
Solidagonic acid is an HSET motor inhibitor that facilitates the conversion of abnormal monopolar spindles to bipolar spindles, thus promoting proper mitotic progression. This compound has been shown to suppress cell death in fission yeast and can revert monopolar to bipolar spindle morphology. Additionally, Solidagonic acid demonstrates growth inhibitory effects on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam, making it a valuable tool for studying spindle dynamics and plant development. -
KIF18A Inhibitor
KIF18A-IN-4 is a noncompetitive inhibitor of KIF18A, targeting ATP and microtubule interactions with an IC50 of 6.16 μM. This compound demonstrates selectivity against a wide range of mitotic kinesins and kinases, while not interfering with tubulin assembly. KIF18A-IN-4 is valuable for research applications focused on tumor biology, particularly in studies investigating its anti-tumor properties. -
KIF18A Inhibitor
EX05 is a potent KIF18A inhibitor, exhibiting an IC50 of 8.2 nM. This compound selectively disrupts the function of KIF18A, a motor protein involved in mitotic spindle positioning, making it a valuable tool for cancer research. Its ability to interfere with cell division processes makes EX05 suitable for studying mechanisms of tumorigenesis and potential therapeutic strategies in oncology. -
KIF18A Inhibitor
KIF18A-IN-19 is a potent inhibitor of KIF18A, demonstrating an IC50 of less than 0.1 μM. This compound exhibits significant anti-cancer activity, particularly against ovarian cancer, making it a valuable tool in cancer research. Its mechanism of action and high efficacy establish KIF18A-IN-19 as a promising candidate for investigating the role of KIF18A in tumor biology. -
KIF18A Inhibitor
KIF18A-IN-12 is a potent inhibitor of KIF18A, exhibiting an IC50 value of 45.54 nM. This compound is valuable for investigating the role of KIF18A in cell division and its implications in cancer research. Researchers can utilize KIF18A-IN-12 to study the mechanistic pathways involved in tumorigenesis and explore potential therapeutic strategies targeting this kinesin. -
KIF18A Inhibitor
KIF18A-IN-14 is a selective inhibitor targeting KIF18A, a motor protein involved in spindle dynamics during cell division. This compound exhibits potent anti-proliferative effects, demonstrating IC50 values between 0-0.01 μM for the EX81-A form and 0.01-0.1 μM for its enantiomer, EX81-B, in OVCAR-3 cell lines. KIF18A-IN-14 is valuable for research applications in tumor biology, particularly in studies related to colon, breast, and lung cancers.
